Belgian biotech Agomab Therapeutics today announced a $89 million (82.1 million euros) Series D financing round, with ...

US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...

Intellia Therapeutics reported positive Phase II results for its CRISPR therapy NTLA-2002, showing an 81% reduction in ...

Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart ...

Orion has discontinued its pain management candidate ODM-111 due to a narrow therapeutic window found in toxicology studies.

Advisory Committee on Immunization Practices (ACIP) voted to update the adult age-based pneumococcal vaccination guidelines ...

US privately-held drug developer NImmune Biopharma has acquired development and commercialization rights for omilancor in ...

Sanofi reported Q3 2024 sales growth of 15.7%, reaching 13.4 billion euros ($14.2 billion), with EPS up 12.2% to 2.86 euros.

Johnson & Johnson has secured European approval for the subcutaneous formulation of Darzalex, combined with bortezomib, lenalidomide, and dexamethasone, for newly diagnosed multiple myeloma patients ...

Legend Biotech has reduced Genscript Biotech's control, lowering its voting power below 50%, amid growing US scrutiny of ...

US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research ...

Indian drugmaker Biocon subsidiary Biocon Biologicals has released a new extension study evaluating MYL-1701P, a proposed ...